What is pharmaceutical compounding, and why does it matter for tirzepatide?
Pharmaceutical compounding is the preparation of a customized medication for a specific patient by a licensed pharmacy, based on a clinician’s prescription. It has been practiced for as long as pharmacy has existed. In the modern context, it most commonly fills gaps where a commercially manufactured drug is unavailable in the needed formulation, strength, or supply.
Tirzepatide compounding exists primarily because of the FDA shortage of branded tirzepatide products (Mounjaro, Zepbound). During an active shortage, licensed 503A compounding pharmacies can legally prepare tirzepatide for individual patients under a valid prescription. This shortage-based exemption is the legal basis for compounded tirzepatide’s availability through telehealth platforms.
Compounded tirzepatide is not the same drug as Mounjaro or Zepbound. It is not FDA-approved. What it is: a clinician-prescribed, pharmacy-prepared preparation containing the same active molecule, made under standards that vary significantly by pharmacy — which is exactly why understanding those standards matters.
503A vs. 503B: the distinction that matters
The two primary categories of licensed compounding facilities in the US are 503A pharmacies and 503B outsourcing facilities. They operate under different regulatory frameworks with meaningfully different implications.
503A pharmacies
A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act. It compounds medications patient-by-patient, with each preparation made in response to a valid prescription for a specific individual. 503A pharmacies are licensed by state pharmacy boards, not directly by the FDA, though federal law sets baseline requirements including the use of USP-compliant manufacturing practices, the use of pharmaceutical-grade bulk drug substances, and restrictions on which substances can be compounded.
503B outsourcing facilities
A 503B facility compounds in larger volumes without patient-specific prescriptions. It registers directly with the FDA and operates under FDA inspection and cGMP (current Good Manufacturing Practices) requirements. 503B facilities serve hospitals, surgical centers, and other institutional buyers rather than individual patients directly.
Our pharmacy standard
PepScribe’s pharmacy standard is 503A-only: licensed, state-inspected compounding pharmacies preparing your prescription individually, using pharmaceutical-grade bulk drug substances with no hidden overseas supply chain. No 503B. No international compounding.
Sterile compounding: why USP <797> compliance is non-negotiable
Tirzepatide is administered by subcutaneous injection. That means the preparation must be sterile — free of microbial contamination, particulates, and pyrogens. Sterile compounding failures can cause serious infections, including sepsis. This is not a remote theoretical risk; FDA enforcement actions against compounding pharmacies have frequently cited sterility failures.
USP General Chapter <797> sets the standards for pharmaceutical sterile compounding in the United States. A compliant pharmacy operates in an ISO-classified cleanroom environment, conducts environmental monitoring, performs sterility and endotoxin testing, and maintains written procedures for every step of the process.
When evaluating a tirzepatide compounding pharmacy, whether through a telehealth platform or independently, asking about USP <797> compliance is not excessive due diligence. It is a basic question about whether the product you are injecting has been prepared to an appropriate standard of safety.
Sourcing: pharmaceutical grade from US suppliers
The tirzepatide that goes into a compounded preparation starts as a bulk drug substance — a raw active ingredient purchased by the pharmacy from a chemical or pharmaceutical supplier. The quality of that starting material directly affects the quality of the finished preparation.
Pharmaceutical-grade bulk drug substances sourced from US suppliers or from suppliers registered with the FDA carry a meaningfully different risk profile than bulk peptides sourced from overseas chemical manufacturers with no pharmaceutical-grade oversight. The phrase “no hidden overseas supply chain” is not a marketing slogan — it is a description of a sourcing practice with genuine quality implications.
A pharmacy that cannot or will not tell you where its bulk drug substances come from is a meaningful red flag.
What questions should you ask before filling a tirzepatide prescription?
Whether you are evaluating a telehealth platform or a pharmacy directly, these questions help you assess whether the pharmacy meets a reasonable standard.
- Is the pharmacy a licensed 503A facility? Can you name the state where it is licensed? Can I verify the license?
- Does the pharmacy follow USP <797> standards for sterile compounding? If not, why not?
- Where is the tirzepatide bulk drug substance sourced? Is it from a US-registered supplier?
- Is there a pharmacist I can contact with clinical questions?
- How is the medication shipped and stored? Tirzepatide requires appropriate cold-chain handling.
The regulatory landscape in 2026
Compounded tirzepatide’s availability is tied to the FDA shortage status of branded products. The FDA has been actively evaluating this market, and the rules around compounding GLP-1 medications are subject to change as branded product supply stabilizes. Working through a platform that stays current with compounding law — and discloses what pharmacy it uses — is the appropriate way to navigate this environment.
A licensed telehealth platform connected to a vetted 503A pharmacy is not the same as a gray-market peptide vendor. The distinction matters legally, clinically, and practically.
Frequently asked questions
What is a 503A compounding pharmacy?
A 503A compounding pharmacy is a state-licensed pharmacy that prepares customized medications to a licensed clinician's prescription for individual patients. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies can compound medications that are not commercially available in exactly the needed formulation, or that are on an FDA shortage list. They are regulated by state pharmacy boards and must comply with USP compounding standards.
Can a 503A pharmacy legally make compounded tirzepatide?
During an active FDA shortage of branded tirzepatide, licensed 503A pharmacies may compound tirzepatide for individual patients under a valid clinician prescription. This is a time-limited exemption tied to the shortage status. If the shortage is resolved, the rules may change. Always use a pharmacy that is actively licensed in your state.
What is the difference between 503A and 503B compounding pharmacies?
503A pharmacies compound medications patient-by-patient under individual prescriptions and are licensed by state pharmacy boards. 503B outsourcing facilities compound in bulk without patient-specific prescriptions and are regulated directly by the FDA. PepScribe's pharmacy standard is 503A-only. No 503B, no international compounding, no overseas supply chain.
How do I know if a tirzepatide compounding pharmacy is legitimate?
A legitimate 503A compounding pharmacy will be licensed in your state, can confirm its National Provider Identifier (NPI), follows USP Chapter <797> sterile compounding standards, uses US-sourced pharmaceutical-grade bulk drug substances, and provides a pharmacist contact for clinical questions. A telehealth platform should be able to tell you exactly which pharmacy fulfills its prescriptions.
Is compounded tirzepatide safe?
Safety depends heavily on the pharmacy. Compounded tirzepatide from a licensed 503A pharmacy following USP sterile compounding standards and using pharmaceutical-grade US-sourced ingredients carries a materially different risk profile than products from gray-market vendors with no quality controls. No compounded medication is FDA-approved, but a licensed 503A pharmacy is subject to meaningful oversight. An unlicensed vendor is not.